Search

Your search keyword '"Badbaran, Anita"' showing total 308 results
Start Over Author "Badbaran, Anita"
308 results on '"Badbaran, Anita"'

4. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Author

Gagelmann, Nico, Badbaran, Anita, Salit, Rachel B., Schroeder, Thomas, Gurnari, Carmelo, Pagliuca, Simona, Panagiota, Victoria, Rautenberg, Christina, Cassinat, Bruno, Thol, Felicitas, Wolschke, Christine, Robin, Marie, Heuser, Michael, Rubio, Marie-Thérèse, Maciejewski, Jaroslaw P., Reinhardt, Hans Christian, Scott, Bart L., and Kröger, Nicolaus

Published
2023
Full Text
View/download PDF

6. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis

Author

Fischbach, Felix, primary, Richter, Johanna, additional, Pfeffer, Lena Kristina, additional, Fehse, Boris, additional, Berger, Susanna Carolina, additional, Reinhardt, Stefanie, additional, Kuhle, Jens, additional, Badbaran, Anita, additional, Rathje, Kristin, additional, Gagelmann, Nico, additional, Borie, Dominic, additional, Seibel, Johan, additional, Ayuk, Francis, additional, Friese, Manuel A., additional, Heesen, Christoph, additional, and Kröger, Nicolaus, additional

Published
2024
Full Text
View/download PDF

10. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation

Author

Gagelmann, Nico, Badbaran, Anita, Beelen, Dietrich W., Salit, Rachel B., Stölzel, Friedrich, Rautenberg, Christina, Becker, Heiko, Radujkovic, Aleksandar, Panagiota, Victoria, Bogdanov, Rashit, Christopeit, Maximilian, Park, Yong, Nibourel, Olivier, Luft, Thomas, Koldehoff, Michael, Corsten, Maarten, Heuser, Michael, Finke, Jürgen, Kobbe, Guido, Platzbecker, Uwe, Robin, Marie, Scott, Bart L., and Kröger, Nicolaus

Published
2021
Full Text
View/download PDF

12. Peripheral and portal venous KRAS ctDNA detection as independent prognostic markers of early tumour recurrence in pancreatic ductal adenocarcinoma

Author

Nitschke, Christine, primary, Markmann, Benedikt, additional, Walter, Philipp, additional, Badbaran, Anita, additional, Tölle, Marie, additional, Kropidlowski, Jolanthe, additional, Belloum, Yassine, additional, Goetz, Mara R., additional, Bardenhagen, Jan, additional, Stern, Louisa, additional, Tintelnot, Joseph, additional, Schönlein, Martin, additional, Sinn, Marianne, additional, van der Leest, Paul, additional, Simon, Ronald, additional, Heumann, Asmus, additional, Izbicki, Jakob R., additional, Pantel, Klaus, additional, Wikman, Harriet, additional, and Uzunoglu, Faik G., additional

Published
2023
Full Text
View/download PDF

17. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation

Author

Kröger, Nicolaus, Panagiota, Victoria, Badbaran, Anita, Zabelina, Tatjana, Triviai, Ioanna, Araujo Cruz, Michelle Maria, Shahswar, Rabia, Ayuk, Francis, Gehlhaar, Marten, Wolschke, Christine, Bollin, Robin, Walter, Carolin, Dugas, Martin, Wiehlmann, Lutz, Lehmann, Ulrich, Koenecke, Christian, Chaturvedi, Anuhar, Alchalby, Haefaa, Stadler, Michael, Eder, Matthias, Christopeit, Max, Göhring, Gudrun, Koenigsmann, Michael, Schlegelberger, Brigitte, Kreipe, Hans-Heinrich, Ganser, Arnold, Stocking, Carol, Fehse, Boris, Thol, Felicitas, and Heuser, Michael

Published
2017
Full Text
View/download PDF

18. Peripheral and Portal VenousKRASctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma

Author

Nitschke, Christine, primary, Markmann, Benedikt, additional, Walter, Philipp, additional, Badbaran, Anita, additional, Tölle, Marie, additional, Kropidlowski, Jolanthe, additional, Belloum, Yassine, additional, Goetz, Mara R, additional, Bardenhagen, Jan, additional, Stern, Louisa, additional, Tintelnot, Joseph, additional, Schönlein, Martin, additional, Sinn, Marianne, additional, van der Leest, Paul, additional, Simon, Ronald, additional, Heumann, Asmus, additional, Izbicki, Jakob R, additional, Pantel, Klaus, additional, Wikman, Harriet, additional, and Uzunoglu, Faik G, additional

Published
2023
Full Text
View/download PDF

19. Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR

Author

Klyuchnikov, Evgeny, primary, Langebrake, Claudia, additional, Badbaran, Anita, additional, Dadkhah, Adrin, additional, Massoud, Radwan, additional, Freiberger, Petra, additional, Ayuk, Francis, additional, Janson, Dietlinde, additional, Wolschke, Christine, additional, Bacher, Ulrike, additional, and Kröger, Nicolaus, additional

Published
2022
Full Text
View/download PDF

20. Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation

Author

Gagelmann, Nico, primary, Badbaran, Anita, additional, Wolschke, Christine, additional, Adjallé, Raissa, additional, Janson, Dietlinde, additional, Berger, Carolina, additional, Klyuchnikov, Evgeny, additional, Fehse, Boris, additional, Ayuk, Francis A., additional, and Kroeger, Nicolaus, additional

Published
2022
Full Text
View/download PDF

21. Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies

Author

Kunte, Ameya Shrinivas, primary, Gagelmann, Nico, additional, Badbaran, Anita, additional, Berger, Carolina, additional, Massoud, Radwan, additional, Klyuchnikov, Evgeny, additional, Wolschke, Christine, additional, Janson, Dietlinde, additional, Fritsche-Friedland, Ulrike, additional, Fehse, Boris, additional, Kroeger, Nicolaus, additional, and Ayuk, Francis A., additional

Published
2022
Full Text
View/download PDF

22. Allogeneic Stem Cell Transplant for Myelodysplastic Syndrome in the New Molecular Era of IPSS-M

Author

Gurnari, Carmelo, primary, Gagelmann, Nico, additional, Badbaran, Anita, additional, Awada, Hussein, additional, Dima, Danai, additional, Pagliuca, Simona, additional, d'Aveni, Maud, additional, Attardi, Enrico, additional, Cerretti, Raffaella, additional, Christine, Wolschke, additional, Rubio, Marie Thérèse, additional, Maciejewski, Jaroslaw P., additional, and Kröger, Nicolaus, additional

Published
2022
Full Text
View/download PDF

24. TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Author

Gagelmann, Nico, primary, Badbaran, Anita, additional, Salit, Rachel Beth, additional, Schroeder, Thomas, additional, Gurnari, Carmelo, additional, Pagliuca, Simona, additional, Ganser, Arnold, additional, Rautenberg, Christina, additional, Cassinat, Bruno, additional, Thol, Felicitas R, additional, Wolschke, Christine, additional, Robin, Marie, additional, Heuser, Michael, additional, Rubio, Marie Thérèse, additional, Maciejewski, Jaroslaw P., additional, Reinhardt, Hans Christian, additional, Scott, Bart L., additional, and Kroeger, Nicolaus, additional

Published
2022
Full Text
View/download PDF

25. High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis

Author

Gagelmann, Nico, Salit, Rachel B., Schroeder, Thomas, Badbaran, Anita, Rautenberg, Christina, Panagiota, Victoria, Wolschke, Christine, Thol, Felicitas, Cassinat, Bruno, Robin, Marie, Heuser, Michael, Reinhardt, Christian, Scott, Bart L., and Kröger, Nicolaus

Subjects
Medizin, Hematology
Abstract

There is no direct evidence to recommend specific conditioning intensities in myelofibrosis undergoing allogeneic hematopoietic cell transplantation, especially in the molecular era. We aimed to compare outcomes of reduced intensity (RIC) or myeloablative conditioning (MAC) transplantation in myelofibrosis with molecular information. The study included 645 genetically annotated patients (with at least driver mutation status available), of whom 414 received RIC and 231 patients received MAC. The median follow-up time from transplantation was 6.0 years for RIC and 9.4 years for MAC. The 6-year overall survival rates for RIC and MAC were 63% (95% confidence interval [CI], 58%-68%) and 59% (95% CI, 52%-66%; P = 0.34) and progression-free survival was 52% (95% CI, 47%-57%) and 52% (95% CI, 45%-59%; P = 0.64). The 2-year cumulative incidence of nonrelapse mortality was 26% (95% CI, 21%-31%) for RIC and 29% (95% CI, 23%-34%) for MAC (P = 0.51). In terms of progression/relapse, the 2-year cumulative incidence was 10% (95% CI, 5%-19%) for RIC and 9% (95% CI, 4%-14%) for MAC (P = 0.46). Higher intensity conditioning did not seem to improve outcomes for higher-risk disease, according to mutational, cytogenetic, and clinical profile. In contrast, patients with reduced performance status, matched unrelated donors, and ASXL1 mutations appeared to benefit from RIC in terms of overall survival. CA extern

Published
2022

26. Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy

Author

Berger, Susanna Carolina, primary, Fehse, Boris, additional, Akyüz, Nuray, additional, Geffken, Maria, additional, Wolschke, Christine, additional, Janson, Dietlinde, additional, Gagelmann, Nico, additional, Luther, Marlene, additional, Wichmann, Dominic, additional, Frenzel, Christian, additional, Thayssen, Guenther, additional, Alegiani, Anna, additional, Badbaran, Anita, additional, Zeschke, Silke, additional, Dierlamm, Judith, additional, Kröger, Nicolaus, additional, and Ayuk, Francis A., additional

Published
2022
Full Text
View/download PDF

29. Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Author

Kröger, Nicolaus, Badbaran, Anita, Zabelina, Tatjana, Ayuk, Francis, Wolschke, Christine, Alchalby, Haefaa, Klyuchnikov, Evgeny, Atanackovic, Djordje, Schilling, Georgia, Hansen, Timon, Schwarz, Sabine, Heinzelmann, Marion, Zeschke, Silke, Bacher, Ulrike, Stübig, Thomas, Fehse, Boris, and Zander, Axel R.

Published
2013
Full Text
View/download PDF

30. Individualized busulfan dosing improves outcomes compared to fixed dose administration in pre-transplant MRD positive AML patients with intermediate risk undergoing allogeneic stem cell transplantation in CR

Author

Klyuchnikov, Evgeny, Langebrake, Claudia, Badbaran, Anita, Dadkhah, Adrin, Massoud, Radwan, Freiberger, Petra, Ayuk, Francis, Janson, Dietlinde, Wolschke, Christine, Bacher, Ulrike, and Kröger, Nicolaus

Subjects
610 Medizin und Gesundheit
Abstract

Pre-transplant minimal residual disease (MRD) impacts negatively on post-transplant relapse risk in AML. Therapeutic drug monitoring by calculating area-under-the-curve (AUC) was developed to optimize busulfan exposure. Here, we compared post-transplant outcomes after individualized versus fixed busulfan dosage in intermediate-risk AML who achieved CR prior to allograft focusing on pre-transplant flow-MRD. 87 patients (median, 56 years) with intermediate-risk AML and pre-transplant flow-MRD ("different from normal") were included. 32 patients received individualized busulfan; 54 fixed dosage. Individualized dosage was adjusted in 25/32 patients: increased, n = 18/25 (72%); decreased: n = 7/25 (28%). After median follow-up of 27 months, we observed lower 3-year relapses (6%, 2-19% vs 35%, 23-49% p = 0.02), improved 3-year LFS (78%, 54-91% vs 55%, 40-70% p = 0.009) and -OS (82%, 60-93% vs 69%, 54-81% p = 0.05) after individualized compared to fixed Bu. NRM and acute GvHD were not different. In multivariate analysis, fixed Bu showed unfavorable impact on OS (HR 4.6, p = 0.044), LFS (HR 3.6, p = 0.018) and relapses (HR 3.6, p = 0.033). Fixed Bu also had unfavorable impact on LFS (3.6, 1.1-12.6, p = 0.041) in pre-transplant MRD-positive patients. Individualized, AUC-based, busulfan is associated with lower relapses in intermediate-risk AML patients allografted in CR and may overcome pre-transplant MRD-positivity.

Published
2022
Full Text
View/download PDF

31. Post-transplant day +100 MRD detection rather than mixed chimerism predicts relapses after allo-SCT for intermediate risk AML patients transplanted in CR

Author

Klyuchnikov, Evgeny, Badbaran, Anita, Massoud, Radwan, Fritsche-Friedland, Ulrike, Freiberger, Petra, Ayuk, Francis, Wolschke, Christine, Bacher, Ulrike, and Kröger, Nicolaus

Subjects
body regions, hemic and lymphatic diseases, 610 Medicine & health
Abstract

BACKGROUND Chimerism and minimal residual disease (MRD) are suggested to be prognostic for post-transplant relapses in AML patients. Nevertheless, the predictive values of both approaches in homogeneous population remain underinvestigated. Here, we suggest that MRD may have a higher predictive value for relapses than mixed chimerism (MC) in intermediate risk AML patients. PATIENTS AND METHODS 79 patients with intermediate risk AML (male, n=40, median age, 57 (19-77)) were included. MRD detection on day +100 was performed in bone marrow (multiparameter flow cytometry and quantitative real-time PCR for NPM1-mutated patients). Chimerism analysis was measured in peripheral blood. MC was defined as persistence of

Published
2022
Full Text
View/download PDF

32. Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.

Author

Nitschke, Christine, Markmann, Benedikt, Walter, Philipp, Badbaran, Anita, Tölle, Marie, Kropidlowski, Jolanthe, Belloum, Yassine, Goetz, Mara R., Bardenhagen, Jan, Stern, Louisa, Tintelnot, Joseph, Schönlein, Martin, Sinn, Marianne, van der Leest, Paul, Simon, Ronald, Heumann, Asmus, Izbicki, Jakob R., Pantel, Klaus, Wikman, Harriet, and Uzunoglu, Faik G.

Published
2023
Full Text
View/download PDF

33. Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR

Author

Klyuchnikov, Evgeny, Langebrake, Claudia, Badbaran, Anita, Dadkhah, Adrin, Massoud, Radwan, Freiberger, Petra, Ayuk, Francis, Janson, Dietlinde, Wolschke, Christine, Bacher, Ulrike, and Kröger, Nicolaus

Subjects
STEM cell transplantation, ACUTE myeloid leukemia, GRAFT versus host disease, BUSULFAN, DRUG monitoring, HEMATOPOIETIC stem cell transplantation, KIDNEY failure
Abstract

Pre‐transplant minimal residual disease (MRD) impacts negatively on post‐transplant relapse risk in acute myeloid leukemia (AML). Therapeutic drug monitoring by calculating area under the curve (AUC) was developed to optimize busulfan (Bu) exposure. Here, we compared post‐transplant outcomes after individualized versus fixed busulfan dosage in intermediate‐risk AML who achieved CR prior to allograft focusing on pre‐transplant flow‐MRD. Eighty‐seven patients (median, 56 years) with intermediate‐risk AML and pre‐transplant flow‐MRD ("different from normal") were included. Thirty‐two patients received individualized busulfan; 54 fixed dosages. Individualized dosage was adjusted in 25/32 patients: increased, n = 18/25 (72%); decreased: n = 7/25 (28%). After median follow‐up of 27 months, we observed lower 3‐year relapses (6%, 2%–19% vs. 35%, 23%–49% p = 0.02), improved 3‐year leukemia‐free survival (LFS) (78%, 54%–91% vs. 55%, 40%–70% p = 0.009) and − overall survival (OS) (82%, 60%–93% vs. 69%, 54%–81% p = 0.05) after individualized compared to fixed Bu. Non‐relapsed mortality (NRM) and acute graft versus host disease (GvHD) were not different. In multivariate analysis, fixed Bu showed unfavorable impact on OS (hazard ratio [HR] 4.6, p = 0.044), LFS (HR 3.6, p = 0.018) and relapses (HR 3.6, p = 0.033). Fixed Bu also had unfavorable impact on LFS (3.6, 1.1–12.6, p = 0.041) in pre‐transplant MRD‐positive patients. Individualized, AUC‐based, busulfan is associated with lower relapses in intermediate‐risk AML patients allografted in CR and may overcome pre‐transplant MRD‐positivity. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients

Author

Schubert, Maria-Luisa, primary, Berger, Carolina, additional, Kunz, Alexander, additional, Schmitt, Anita, additional, Badbaran, Anita, additional, Neuber, Brigitte, additional, Zeschke, Silke, additional, Wang, Lei, additional, Riecken, Kristoffer, additional, Hückelhoven‑Krauss, Angela, additional, Müller, Ingo, additional, Müller‑Tidow, Carsten, additional, Dreger, Peter, additional, Kröger, Nicolaus, additional, Ayuk, Francis, additional, Schmitt, Michael, additional, and Fehse, Boris, additional

Published
2022
Full Text
View/download PDF

35. Enhanced immune reconstitution of γδ T cells after allograft overcomes negative impact of pre-transplant MRD positive status in AML patients.: γδ T cells and MRD+ AML

Author

Klyuchnikov, Evgeny, Badbaran, Anita, Massoud, Radwan, Fritsche-Friedland, Ulrike, Janson, Dietlinde, Ayuk, Francis, Wolschke, Christine, Bacher, Vera, and Kröger, Nicolaus

Subjects
hemic and lymphatic diseases, 610 Medicine & health
Abstract

BACKGROUND Minimal residual disease (MRD) prior to allogeneic stem cell transplantation (allo-SCT) in AML is a poor risk factor for outcome. The γδ T cells represents a unique minority lymphocyte population which is preferentially located in peripheral tissues, can recognize antigens in non-MHC restricted manner and plays a "bridging" role between innate and adaptive immune system. OBJECTIVES In this study, we investigated a potential graft-vs-leukaemia effect of γδ T cells reconstitution post-transplant in AML patients with pre-transplant positive minimal/measurable disease status (MRD+). STUDY DESIGN We investigated a potential graft-vs-leukaemia effect of γδ T cells reconstitution post-transplant in AML patients with pre-transplant positive MRD+. MRD assessment was performed in 202 patients (MRD+, n=100) with multicolored flow cytometry ("different from normal" strategy). Analysis for absolute concentrations of CD3+, CD4+, CD8+, NK, and γδ T cells were performed by flow cytometry according to an internal protocol at day +30 and +100 post-transplant. Differences between categorical and continuous variables were determined by Chi-square and Student's T-test, respectively. The Mann-Whitney test was used to compare medians of continuous variables. Spearman correlation was used for nonparametric assessment of correlation between different cell subsets during immune reconstitution. Kaplan Meier survival analysis and Cox regression analysis were used to investigate the associations between immune reconstitution and survival outcomes. Grays' analysis was used to compute incidences of relapses, non-relapse mortality (NRM) and graft-vs-host disease (GvHD). RESULTS Follow-up for survivors was 28 months (3-59). Younger age (≤58) of recipient and donor (

Published
2021

36. Digital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues

Author

Badbaran, Anita, primary, Mailer, Reiner K., additional, Dahlke, Christine, additional, Woens, Jannis, additional, Fathi, Anahita, additional, Mellinghoff, Sibylle C., additional, Renné, Thomas, additional, Addo, Marylyn M., additional, Riecken, Kristoffer, additional, and Fehse, Boris, additional

Published
2021
Full Text
View/download PDF

37. Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis

Author

Gagelmann, Nico, primary, Badbaran, Anita, additional, Ditschkowski, Markus, additional, Panagiota, Victoria, additional, Cassinat, Bruno, additional, Heuser, Michael, additional, Thol, Felicitas, additional, Wolschke, Christine, additional, Salit, Rachel B., additional, Robin, Marie, additional, Beelen, Dietrich W., additional, Scott, Bart L., additional, and Kroeger, Nicolaus, additional

Published
2021
Full Text
View/download PDF

44. Impact of Mutation Profile in Chronic Myelomonocytic Leukemia undergoing Allogeneic Hematopoietic Cell Transplantation

Author

Gagelmann, Nico, Badbaran, Anita, Bogdanov, Rashit, Stoelzel, Friedrich, Rautenberg, Christina, Nibourel, Olivier, Becker, Heiko, Radujkovic, Aleksandar, Dreger, Peter, Christopeit, Maximilian, Finke, Juergen, Platzbecker, Uwe, Koldehoff, Michael, Ditschkowski, Markus, Beelen, Dietrich, Robin, Marie, and Kröger, Nicolaus

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2020

49. Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Author

Gagelmann, Nico, primary, Badbaran, Anita, additional, Bogdanov, Rashit, additional, Nibourel, Olivier, additional, Stoelzel, Friedrich, additional, Rautenberg, Christina, additional, Becker, Heiko, additional, Radujkovic, Aleksandar, additional, Koldehoff, Michael, additional, Christopeit, Maximilian, additional, Dreger, Peter, additional, Finke, Jürgen, additional, Kobbe, Guido, additional, Platzbecker, Uwe, additional, Robin, Marie, additional, Beelen, Dietrich W., additional, and Kroeger, Nicolaus, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results